Track the 에이프릴바이오 stock price and the full insider trade history of the company, a listed equity based in South Korea. Shares are quoted on KR KR, under the supervision of DART (FSS). Operating in the Health Care sector, 에이프릴바이오 has logged 40 public disclosures. Market capitalisation: €709.6bn. The latest transaction was reported on 1 July 2026 (Other). Among the most active insiders: 유한양행. Every trade is accessible without an account.
40
Insider Decl.
0
Thresholds
·
20 ops.
Buy Volume
·
8 ops.
Sell Volume
11Σ signal
Informational score on this market. Our backtest validates the signal only on 8 EU venues; elsewhere (notably US markets) insider buys historically invert or do not hold. Not a recommendation.
Fundamental score
Ranked 16,050 of 25,921 companies
44.6
score / 100
Value
31
Quality
58
FCF yld-0.6%
Earn yld-1.6%
EV/EBITDA·
ROE-11%
Gross mgn100%
Net mgn·
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
April Bio is a company operating in the healthcare and pharmaceutical sector, listed on the XKRX market. It focuses on developing innovative biopharmaceutical solutions.